Immune Design Corp. (IMDZ) financial statements (2020 and earlier)

Company profile

Business Address 1616 EASTLAKE AVENUE E.
SEATTLE, WA 98102
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9614110711375
Cash and cash equivalents78724511375
Short-term investments186962  
Restricted cash and investments 6   
Receivables14412
Inventory, net of allowances, customer advances and progress billings01100
Inventory01100
Prepaid expense22321
Other current assets2    
Total current assets:10015311411678
Noncurrent Assets
Property, plant and equipment10010
Deposits noncurrent assets00   
Total noncurrent assets:11010
TOTAL ASSETS:10115411411678
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities999713
Accounts payable12537
Accrued liabilities76545
Employee-related liabilities    1
Estimated litigation liability 67  
Deferred revenue and credits 301
Other undisclosed current liabilities    (2)
Total current liabilities:91519712
Noncurrent Liabilities
Liabilities, other than long-term debt00000
Deferred revenue and credits   0
Other liabilities0000 
Total noncurrent liabilities:00000
Total liabilities:91519712
Stockholders' equity
Stockholders' equity attributable to parent, including:921399510966
Additional paid in capital382375279239157
Accumulated other comprehensive loss(0)(0)(0)  
Accumulated deficit(291)(236)(184)(130)(91)
Other undisclosed stockholders' equity attributable to parent00000
Total stockholders' equity:921399510966
TOTAL LIABILITIES AND EQUITY:10115411411678

Income statement (P&L) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues2713106
Revenue, net713106
Cost of revenue
(Cost of Goods and Services Sold)
(1)(0)(0)(1)(1)
Gross profit:171396
Operating expenses(59)(60)(67)(49)(36)
Other undisclosed operating income10011
Operating loss:(57)(53)(54)(39)(30)
Nonoperating income
(Other Nonoperating income)
21100
Net loss:(55)(52)(54)(39)(30)
Other undisclosed net loss attributable to parent    (4)
Net loss available to common stockholders, diluted:(55)(52)(54)(39)(34)

Comprehensive Income ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(55)(52)(54)(39)(30)
Comprehensive loss:(55)(52)(54)(39)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)(0)  
Comprehensive loss, net of tax, attributable to parent:(55)(52)(54)(39)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: